Background: Protein-energy wasting and chronic inflammation are prevalent in patients with end-stage renal disease (ESRD). We investigated the combination of serum albumin, C-reactive protein (CRP) and body mass index (BMI) at initiation of hemodialysis therapy as a predictor of all-cause and cardiovascular disease (CVD) mortality in Japanese ESRD patients. Methods: A total of 1,228 consecutive Japanese ESRD patients on hemodialysis therapy were enrolled and followed for up to 10 years. Patients were divided into quartiles according to levels of albumin, CRP and BMI. Furthermore, to clarify the joint role of these factors, albumin <3.5 g/dl, CRP >4.0 mg/l and BMI <19.6 were defined as risk factors using receiver operating characteristic analysis; thereafter, patients were divided into groups according to the positive number of these factors. Results: Adjusted hazard ratios (HRs) for lower serum albumin, elevated CRP and lower BMI for 10-year all-cause mortality were 1.97, 3.13 and 2.61, respectively. Regarding the combination of these variables, adjusted HRs for mortality were 2.31, 4.28 and 8.07, respectively, in patients having any one factor, any two factors and all three factors. The C-index for an established risk model with these three positive markers was the most accurate for predicting mortality (0.768), as compared to other models with one or two markers. Similar results were seen for CVD mortality. Conclusions: Serum albumin, CRP and BMI at the start of hemodialysis therapy were able to individually stratify the risk of long-term mortality in ESRD patients. Furthermore, a combination of these variables could more accurately predict mortality.

Keywords:
Albumin, CRP, BMI, Composite, Survival, CVD mortality
1.
Stenvinkel P, Carrero JJ, Axelsson J, et al: Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol 2008;3:505–521.
2.
Cheung AK, Sarnak MJ, Yan G, et al: Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 2000;58:353–362.
3.
Stenvinkel P, Lindholm B: C-reactive protein in end-stage renal disease: are there reasons to measure it? Blood Purif 2005;23:72–78.
4.
Menon V, Greene T, Wang X, et al: C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int 2005;68:766–772.
5.
Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C: Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999;55:648–658.
6.
Lowrie EG, Lew NL: Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990;15:458–482.
7.
Friedman AN, Fadem SZ: Reassessment of albumin as a nutritional marker in kidney disease. J Am Soc Nephrol 2010;21:223–230.
8.
Iseki K, Tozawa M, Yoshi S, Fukiyama K: Serum C-reactive protein (CRP) and risk of death in chronic dialysis patients. Nephrol Dial Transplant 1999;14:1956–1960.
9.
Kalantar-Zadeh K, Kopple JD, Kilpatrick RD, et al: Association of morbid obesity and weight change over time with cardiovascular survival in hemodialysis population. Am J Kidney Dis 2005;46:489–500.
10.
Kalantar-Zadeh K, Kuwae N, Wu DY, et al: Associations of body fat and its changes over time with quality of life and prospective mortality in hemodialysis patients. Am J Clin Nutr 2006;83:202–210.
11.
Huang CX, Tighiouart H, Beddhu S, et al: Both low muscle mass and low fat are associated with higher all-cause mortality in hemodialysis patients. Kidney Int 2010;77:624–629.
12.
Ishii H, Toriyama T, Aoyama T, et al: Prognostic values of C-reactive protein levels on clinical outcome after implantation of sirolimus-eluting stents in patients on hemodialysis. Circ Cardiovasc Interv 2009;2:513–518.
13.
Ishii H, Kumada Y, Toriyama T, et al: Prognostic values of C-reactive protein levels on clinical outcome after endovascular therapy in hemodialysis patients with peripheral artery disease. J Vasc Surg 2010;52:854–859.
14.
de Mutsert R, Snijder MB, van der Sman-de Beer F, et al: Association between body mass index and mortality is similar in the hemodialysis population and the general population at high age and equal duration of follow-up. J Am Soc Nephrol 2007;18:967–974.
15.
Zhang L, Kao WH, Berthier-Schaad Y, et al: C-Reactive protein haplotype predicts serum C-reactive protein levels but not cardiovascular disease risk in a dialysis cohort. Am J Kidney Dis 2007;49:118–126.
16.
Coe CL, Love GD, Karasawa M, et al: Population differences in proinflammatory biology: Japanese have healthier profiles than Americans. Brain Behav Immun 2011;25:494–502.
17.
Oldroyd JC, Heald A, Bansal N, et al: Inflammatory markers and growth in South Asian and European origin infants in Britain: the Manchester Children’s Growth and Vascular Health Study. Atherosclerosis 2009;207:227–231.
18.
Wong JS, Port FK, Hulbert-Shearon TE, et al: Survival advantage in Asian American end-stage renal disease patients. Kidney Int 1999;55:2515–2523.
19.
Fouque D, Kalantar-Zadeh K, Kopple J, et al: A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int 2008;73:391–398.
20.
Nakai S, Suzuki K, Masakane I, et al: Overview of regular dialysis treatment in Japan (as of 31 December 2008). Ther Apher Dial 2010;14:505–540.
21.
Mafra D, Guebre-Egziabher F, Fouque D: Body mass index, muscle and fat in chronic kidney disease: questions about survival. Nephrol Dial Transplant 2008;23:2461–2466.
22.
Honda H, Qureshi AR, Heimbürger O, et al: Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis 2006;47:139–148.
23.
Rambod M, Bross R, Zitterkoph J, et al: Association of malnutrition-inflammation score with quality of life and mortality in hemodialysis patients: a 5-year prospective cohort study. Am J Kidney Dis 2009;53:298–309.
24.
Hung AM, Ellis CD, Shintani A, Booker C, Ikizler TA: IL-1β receptor antagonist reduces inflammation in hemodialysis patients. J Am Soc Nephrol 2011;22:437–442.
25.
de Mutsert R, Grootendorst DC, Axelsson J, et al: Excess mortality due to interaction between protein-energy wasting, inflammation and cardiovascular disease in chronic dialysis patients. Nephrol Dial Transplant 2008;23:2957–2964.
26.
Kalantar-Zadeh K, Kopple JD, Block G, et al: A malnutrition-inflammation score is correlated with morbidity and mortality in maintenance hemodialysis patients. Am J Kidney Dis 2001;38:1251–1263.
27.
Sekikawa A, Ueshima H, Kadowaki T, et al: Less subclinical atherosclerosis in Japanese men in Japan than in White men in the United States in the post-World War II birth cohort. Am J Epidemiol 2007;165:617–624.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.